1. METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma.
- Author
-
Thombare, Ketan, Vaid, Roshan, Pucci, Perla, Ihrmark Lundberg, Kristina, Ayyalusamy, Ritish, Baig, Mohammad Hassan, Mendez, Akram, Burgos-Panadero, Rebeca, Höppner, Stefanie, Bartenhagen, Christoph, Sjövall, Daniel, Rehan, Aqsa Ali, Dattatraya Nale, Sagar, Djos, Anna, Martinsson, Tommy, Jaako, Pekka, Dong, Jae-June, Kogner, Per, Johnsen, John Inge, and Fischer, Matthias
- Subjects
HOMEOBOX genes ,GENE expression ,MEDICAL sciences ,GENETIC regulation ,NEURAL crest - Abstract
Neuroblastoma (NB) is the most common extracranial childhood cancer, caused by the improper differentiation of developing trunk neural crest cells (tNCC) in the sympathetic nervous system. The N
6 -methyladenosine (m6 A) epitranscriptomic modification controls post-transcriptional gene expression but the mechanism by which the m6 A methyltransferase complex METTL3/METTL14/WTAP is recruited to specific loci remains to be fully characterized. We explored whether the m6 A epitranscriptome could fine-tune gene regulation in migrating/differentiating tNCC. We demonstrate that the m6 A modification regulates the expression of HOX genes in tNCC, thereby contributing to their timely differentiation into sympathetic neurons. Furthermore, we show that posterior HOX genes are m6 A modified in MYCN-amplified NB with reduced expression. In addition, we provide evidence that sustained overexpression of the MYCN oncogene in tNCC drives METTL3 recruitment to a specific subset of genes including posterior HOX genes creating an undifferentiated state. Moreover, METTL3 depletion/inhibition induces DNA damage and differentiation of MYCN overexpressing cells and increases vulnerability to chemotherapeutic drugs in MYCN-amplified patient-derived xenografts (PDX) in vivo, suggesting METTL3 inhibition could be a potential therapeutic approach for NB. Synopsis: Neuroblastoma (NB) childhood cancers, associated with amplification of the MYCN oncogene, present an undifferentiated phenotype and are challenging to treat. This study reports MYCN cooperation with the m6 A methyltransferase METTL3 promoting epitranscriptome changes and a developmental, aggressive state in early trunk neural crest cells (tNCC). m6 A deposition regulatesHOX gene expression in tNCC, ensuring their proper differentiation into sympathetic neurons. Increased MYCN levels promote METTL3 recruitment and m6 A deposition at specific genes in tNCC, including HOX genes, which maintain an undifferentiated state in NB. Depleting or inhibiting METTL3 in MYCN-driven NB promotes cell differentiation and triggers DNA damage. Inhibiting METTL3 increases NB sensitivity to chemotherapy in mice. MYCN oncogene drives METTL3 recruitment and m6 A deposition at posterior HOX genes, creating an undifferentiated state in early neural crest cells. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF